Ceftaroline: A Success for Biomarker Development
This article was originally published in RPM Report
Executive Summary
The regulatory environment for anti-infective approvals is getting better: that is one message from the positive FDA advisory committee review of Forest’s ceftaroline. A corollary message is that the work on biomarkers and improved endpoints (by groups outside FDA) is having an impact.